Clinical Studies Using TYR PET
| Study | Year | No. of patients | Tumor type | Sensitivity (%) | Remarks and findings |
|---|---|---|---|---|---|
| Pruim (56) | 1995 | 22 | Primary brain | 92 | Specificity 67%; no correlation with grade |
| Heesters (85) | 1998 | 10 | Primary brain | — | PSR within original tumor volume unchanged after radiotherapy |
| Braams (89) | 1996 | 11 | Oral cavity | 83 | In nodal staging, better than MRI or CT; specificity 95% |
| Kole (100) | 1997 | 13 | Breast cancer | 100 | For primary tumor; visually less uptake than for FDG in fibrocystic disease |
| Ginkel (107) | 1999 | 17 | Sarcoma | 82 | Partial vs. complete remission distinguished after chemotherapy; specificity 100% |
| Plaat (106) | 1999 | 21 | Sarcoma | — | Correlation of PSR with Ki-67, not with grade |
| Kole (57) | 1999 | 25 | Sarcoma | — | FDG better for grading; TYR better for correlation with proliferation |
| Kole (111) | 1998 | 10 | Nonseminoma | 20 | |
| Kole (119) | 1997 | 22 | Various types | 94 | Chondrosarcoma not visualized |
| Que (120) | 2000 | 10 | Cervix | 80 | Interfering bone marrow and intestinal uptake present |
PSR = protein synthesis rate.